Definium Therapeutics Unveils Phase 3 Data for Psychedelic-Based Mental Health Treatments
Event summary
- Definium Therapeutics will present topline data from Phase 3 trials of DT120 (lysergide) for Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD) at Psych Congress 2026.
- Six poster presentations scheduled for September 17–18, 2026, including safety profiles, trial designs, and epidemiological research on suicidal ideation.
- DT120 is an orally disintegrating tablet targeting the two largest psychiatric disorders by prevalence.
- Company trades on Nasdaq under the symbol DFTX.
The big picture
Definium’s presentation marks a pivotal moment for psychedelic therapeutics, as the industry shifts from proof-of-concept to scalable mental health solutions. The focus on MDD and GAD—disorders affecting over 40 million Americans—highlights the commercial potential if regulatory and reimbursement barriers are cleared. Success here could validate the broader psychedelics sector, currently valued at $7B with projected 20% CAGR through 2030.
What we're watching
- Regulatory Pathway
- Whether DT120 can navigate DEA rescheduling hurdles for Schedule I controlled substances, a prerequisite for U.S. commercialization.
- Market Differentiation
- How Definium positions DT120 against emerging psychedelic competitors targeting similar indications.
- Clinical Efficacy
- The pace at which Phase 3 data translates into payer coverage and reimbursement decisions for psychedelic-assisted therapies.
Related topics